BICSTA™
Enable the creation of novel immuno-oncology biologics capable of engaging multiple targets
The BICSTA™ platform, a patented technology, maximizes the formation rate of Fc heterodimers. This technology is essential for producing multi-specific drugs, enabling high productivity and target expandability, which results in the highly effective creation of multi-specific drugs.
STARKINE™
Enable the rapid generation of novel cytokine variants designed specifically for each disease
The STARKINE™ platform is a powerful technology that can quickly modulate the affinity, selectivity, and stability of cytokines through rational design and computational modeling. This technology enables the fast screening of cytokine variants optimized for each target disease.
Antibody Targeting
Cytokine
Novel immuno-cytokine biologics that enhance efficacy while minimizing side effects
The ATC technology, utilizing the BICSTA™ platform, involves the development of a novel class of immunotherapeutic agents that combine antibodies with newly created cytokines. This multi-specific drug aims to reduce the side effects associated with traditional cytokines while enhancing efficacy, representing an innovative immuno-oncology treatment.
Pipeline
New drug development
Committed to advancing innovative, multi specific immuno-oncology therapies
Press Release
Latest News
Looking for
Innovation leaders
At Mustbio, we prioritize curiosity, creativity, and teamwork as our core values. Our mission is to develop
groundbreaking immuno-oncology therapies to tackle the serious unmet needs of cancer patients, with the
goal of enabling them to lead healthy and fulfilling lives. We are always on the lookout for highly motivated
individuals to lead the charge in innovation. We invite you to join us on our journey towards this goal.
